Skip to main content
Study Intelligence Example

See how PrismCDM understands a study.

Explore a demonstration Executive Summary generated from publicly available ClinicalTrials.gov registry information. Review the study assessment, contributing complexity indices, operational findings, recommendations, and the provenance information supporting the analysis.

Every displayed value is identified as sourced, PrismCDM-generated, or representative. Engine, assessment, corpus, and build information are shown with the artifact so the analysis can be evaluated in context.

Sample Executive Summary

Demonstration artifact.

Inspect the artifact below. Study identifier, sponsor, and title are presented in demonstration form. The non-endorsement disclaimer at the bottom of the artifact is part of the rendering and travels with every free-tier Executive Summary generated from public registry data.

Executive Summary
NCT02******

Phase III Immunotherapy Plus Chemotherapy Study in Advanced Non-Small-Cell Lung Cancer

Sponsor
Global Oncology Sponsor
Phase
3
Enrollment
616
Executive Assessment
Prism Trial Intelligence Index™v1
Frontline Phase 3 oncology with combination immunotherapy plus chemotherapy
84/ 100
High Complexity
v1 basis
  • Protocol Complexity Index
  • Operational Burden Index
  • Eligibility Strictness Index
Enters in v2 (corpus required)
  • Amendment Risk Index
  • Enrollment Velocity Index
Contributing Sub-Indices
Protocol Complexity Index(PCI)
Available
87/ 100

Combination regimen, mandatory tumor biopsy, multi-arm randomization

Operational Burden Index(OBI)
Available
82/ 100

Visit cadence and procedure load above frontline oncology average

Eligibility Strictness Index(ESI)
Available
71/ 100

Recent diagnosis with no prior systemic therapy narrows screening pool

Amendment Risk Index(ARI)
Coming Soon

Predictive sub-index. Corpus required.

Enrollment Velocity Index(EVI)
Coming Soon

Benchmark sub-index. Corpus required.

Executive Bottom Line
Operational burden is driven by combination dosing logistics and tumor tissue requirements during screening. Eligibility narrows the pool to recently diagnosed patients without prior systemic therapy, which constrains enrollment velocity at community sites.
RecommendationREC-*
Operational Priority
HIGH
Recommendation

Expand site network to include academic and tertiary community oncology sites.

Expected Impact

Improve screening reach across the eligible patient population.

Evidence
FIND-*
Generated
Date
Current generation date
Engine
Current platform version
Assessment
Current assessment model
Corpus Snapshot
Current corpus
Build
Current release

Demonstration generated by PrismCDM using publicly available ClinicalTrials.gov protocol information (NCT02******). This analysis was independently produced by PrismCDM and has not been reviewed or endorsed by the study sponsor.

More Examples

Additional examples are being prepared.

Examples across oncology, cardiology, rare disease, medical device, and cell therapy will publish here after each artifact completes internal review and source- fidelity validation.

We publish an example only when it is a genuine generation on a real protocol against the live engine, with the full anchor chain attached. Nothing representative appears in this section.

Early Access

Generate an Executive Summary on your NCT.

Free from a ClinicalTrials.gov NCT. Upgrade to the paid Study Intelligence Report for complete analysis with source-backed recommendations.